- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4196 - 1,2,4-Triazoles
Patent holdings for IPC class A61K 31/4196
Total number of patents in this class: 3029
10-year publication summary
|
184
|
227
|
254
|
237
|
212
|
185
|
178
|
206
|
222
|
97
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Axsome Therapeutics, Inc. | 338 |
78 |
| Synta Pharmaceuticals Corp. | 146 |
69 |
| F. Hoffmann-La Roche AG | 7847 |
46 |
| Novartis AG | 10340 |
43 |
| Karyopharm Therapeutics Inc. | 142 |
40 |
| Merck Sharp & Dohme LLC | 3736 |
33 |
| Genentech, Inc. | 4090 |
31 |
| Hoffmann-La Roche Inc. | 3722 |
30 |
| Bayer Pharma AG | 1025 |
30 |
| Boehringer Ingelheim International GmbH | 4494 |
29 |
| Ardea Biosciences, Inc. | 69 |
27 |
| Gilead Sciences, Inc. | 2200 |
27 |
| Pfizer Inc. | 3374 |
24 |
| The Regents of the University of California | 20594 |
23 |
| Bristol-myers Squibb Company | 4797 |
22 |
| Eli Lilly and Company | 4050 |
22 |
| Bayer AG | 3465 |
19 |
| Havah Therapeutics Pty Ltd | 20 |
19 |
| BASF SE | 21150 |
18 |
| Theravance Biopharma R&D IP, LLC | 417 |
18 |
| Other owners | 2381 |